Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin

Hepatology

Volumn 24, Issue 4 I, 1996, Pages 796-801

  Fromm, Martin Friedrich ^a   Busse, Dagmar ^b   Kroemer, Heyo Klaus ^b   Eichelbaum, Michel ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; RIFAMPICIN; VERAPAMIL;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PR INTERVAL; PRIORITY JOURNAL; STEREOSPECIFICITY;

EID: 0029786432     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008855178     Document Type: Article

References (47)

1. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-1036.
2. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878.
3. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-259.
4. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994;22:947-955.
5. De Waziers I, Cugnenc PH, Yang CS, Leroux J-P, Beaune PH. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253:387-394.
6. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-160.
7. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-1490.
8. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52:453-457.
9. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
10. Eichelbaum M, Dengler HJ, Somogyi A, von Unruh GE. Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Eur J Clin Pharmacol 1981; 19:127-131.
11. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992;260:1052-1057.
12. Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf R, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348:332-337.
13. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995;353:116-121.
14. Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M. The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 1985;109:210-217.
15. Echizen H, Vogelgesang B, Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985;38:71-76.
16. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Int Med 1992;152:711-716.
17. Rieder HL, Cauthen GM, Kelly GD, Bloch AB, Snider DE. Tuberculosis in the United States. JAMA 1989;262:385-389.
18. Rahn KH, Mooy J, Böhm R, Von de Vet A. Reduction of bioavailability of verapamil by rifampin. N Engl J Med 1985;312:920-921.
19. Barbarash RA. Verapamil-rifampin interaction. Drug Intell Clin Pharm 1985;19:559-560.
20. Barbarash RA, Bauman JL, Fischer JH, Kondos GT, Batenhorst RL. Near-total reduction in verapamil bioavailability by rifampin. Chest 1988;94: 954-959.
21. Fischer C, Schönberger F, Muck W, Heuck K, Eichelbaum M. Simultaneous assessment of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral stationary-phase high-performance liquid chromatography and gas chromatography/mass spectroscopy combined with a stable isotope technique. J Pharm Sci 1993;82:244-250.
22. Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK. Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther 1990; 253:1042-1048.
23. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and applications. Philadelphia: Lea & Febiger, 1995.
24. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc Res 1976;10:1-8.
25. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver volume and apparent liver blood flow in healthy man. HEPATOLOGY 1989;9:297-301.
26. Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981;12:51-60.
27. Gross AS, Heuer B, Eichelbaum M. Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol 1988;37:4623-4627.
28. Ohnhaus EE, Coninx S, Ramos MR, Noelpp U. Liver blood flow and enzyme induction in man. Br J Clin Pharmacol 1976;3:352-353.
29. Pirttiaho HI, Sotaniemi EA, Pelkonen RO, Pitkänen U. Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants. Eur J Clin Pharmacol 1982;22:441-445.
30. Bauer LA, Stenwall M, Horn JR, Davis R, Opheim K, Greene L. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther 1986;40:239-242.
31. Meredith PA, Elliott HL, Pasanisi F, Kelman AW, Sumner DJ, Reid JL. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol 1985;20:101-106.
32. Bolondi L. The value of Doppler US in the study of hepatic hemodynamics. Consensus conference. J Hepatol 1990;10:353-355.
33. Reiss WG, Bauer LA, Horn JR, Zierler BK, Easterling TR, Strandness DE. The effects of oral nifedipine on hepatic blood flow in humans. Clin Pharmacol Ther 1991;50:379-384.
34. McDonnell WM, Scheiman JM, Traber PG. Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract. Gastroenterology 1992;103:1509-1516.
35. Morel F, Beaune PH, Ratanasavanh D, Flinois J-P, Yang CS, Guengerich FP, Guillouzo A. Expression of cytochrome P-450 enzymes in cultured human hepatozytes. Eur J Biochem 1990;191:437-444.
36. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-299.
37. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wschr 1985;63:1205-1211.
38. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-491.
39. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, Neuvonen PJ. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
40. Eichelbaum M, Somogyi A, Unruh GEv, Dengler HJ. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur J Clin Pharmacol 1981;19:133-137.
41. Woodcock BG, Schulz W, Kober G, Rietbrock N. Direct determination of hepatic extraction of verapamil in cardiac patients. Clin Pharmacol Ther 1981;30:52-56.
42. Eichelbaum M, Albrecht M, Kliems G, Schäfer K, Somogyi A. Influence of mesocaval shunt surgery on verapamil kinetics, bioavailability and response. Brit J Clin Pharmacol 1980;10:527-530.
43. Ariens EJ. Nonchiral, homochiral and composite chiral drugs. Trends Pharmacol Sci 1993;14:68-75.
44. Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 1994;89:2396-2400.
45. Smith DA, Chandler MHH, Shedlofsky SI, Wedlund PJ, Blouin RA. Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin. Br J Clin Pharmacol 1991;32:735-739.
46. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
47. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 1992;41:1047-1055.